Anebulo Pharmaceuticals Inc (ANEB)

$2.37 -0.04 (-1.55%)
Market Cap 98.90M
Revenue (ttm) 0.00
Net Income (ttm) -8.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 147,200
Avg Vol 478,698
Day's Range N/A - N/A
Shares Out 41.09M
Stochastic %K 17%
Beta -0.88
Analysts Sell
Price Target $4.50

Company Profile

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2...

Industry: Biotechnology
Sector: Healthcare
Phone: 512 598 0931
Address:
1017 Ranch Road 620 South, Suite 107, Lakeway, United States
longandon
longandon Jul. 31 at 7:15 PM
$ANEB so this English aron guy is kinda like that Tang guy that buys up bio or take the private? Anyone know about his previous companies ?
0 · Reply
YouVSYou
YouVSYou Jul. 27 at 3:12 AM
$ANEB $LIDR classic Golden Cross Launch pads We’ve found a few that haven’t gotten sent yet 😀
0 · Reply
davis8uni
davis8uni Jul. 25 at 12:25 PM
$ANEB
0 · Reply
davis8uni
davis8uni Jul. 25 at 2:00 AM
$ANEB
0 · Reply
davis8uni
davis8uni Jul. 24 at 12:12 PM
$ANEB
0 · Reply
YGLD
YGLD Jul. 24 at 11:23 AM
No +100% Gappers 😴 No Crazy PR Runners 😴 No After Hours Stock From Last Night Making Any Moves 😴 Very Low Volume Day Ahead 📉 $DNUT $ANEB $YYAI $AMOD $SPY
0 · Reply
davis8uni
davis8uni Jul. 24 at 9:09 AM
$ANEB Appreciate the transparency! He is killing it. Must watch! https://www.youtube.com/watch?v=xUO2eE5IbvM
0 · Reply
M1LL5
M1LL5 Jul. 24 at 3:29 AM
$ANEB $DNUT 👀
0 · Reply
YGLD
YGLD Jul. 24 at 1:21 AM
A Stop Loss Is An Insurance Policy Against A Big Loss 📝 $DNUT $ANEB $YYAI $AMOD $SPY
2 · Reply
YGLD
YGLD Jul. 24 at 1:20 AM
It Cost $0.00 To Wait For A Good Trading Setup 📝 $DNUT $ANEB $YYAI $AMOD $SPY
0 · Reply
Latest News on ANEB
Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock

Jul 23, 2025, 8:00 AM EDT - 20 days ago

Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates

May 13, 2025, 4:05 PM EDT - 3 months ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

Feb 14, 2025, 4:05 PM EST - 6 months ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

Dec 23, 2024, 9:15 AM EST - 8 months ago

Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

Nov 13, 2024, 4:05 PM EST - 9 months ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

Sep 25, 2024, 4:05 PM EDT - 11 months ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

Jul 22, 2024, 7:00 AM EDT - 1 year ago

Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

Galehead Development to Collaborate With Rivian Automotive on Renewable Energy Project Development

May 15, 2024, 1:15 PM EDT - 1 year ago

Galehead Development to Collaborate With Rivian Automotive on Renewable Energy Project Development

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

May 15, 2024, 1:05 PM EDT - 1 year ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

Feb 13, 2024, 4:05 PM EST - 1 year ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates

Nov 14, 2023, 4:05 PM EST - 1 year ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

Oct 6, 2023, 4:06 PM EDT - 2 years ago

Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

Anebulo Pharmaceuticals Announces New CEO

Oct 6, 2023, 4:06 PM EDT - 2 years ago

Anebulo Pharmaceuticals Announces New CEO

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates

Sep 20, 2023, 4:29 PM EDT - 2 years ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences

Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

May 11, 2023, 8:00 AM EDT - 2 years ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

Mar 28, 2023, 8:00 AM EDT - 2 years ago

Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

Mar 8, 2023, 8:00 AM EST - 2 years ago

Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates

Feb 10, 2023, 8:38 AM EST - 2 years ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates

Anebulo: Interesting Drug For Cannabis Intoxication, But The Market Potential Remains Unclear

Jan 27, 2023, 3:49 PM EST - 2 years ago

Anebulo: Interesting Drug For Cannabis Intoxication, But The Market Potential Remains Unclear

Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

Jan 9, 2023, 8:00 AM EST - 2 years ago

Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates

Nov 10, 2022, 8:00 AM EST - 2 years ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

Nov 1, 2022, 4:00 PM EDT - 3 years ago

Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing

Sep 26, 2022, 7:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing

Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Sep 26, 2022, 7:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022

Sep 20, 2022, 8:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress

Sep 9, 2022, 8:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress

Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26

Aug 23, 2022, 5:00 PM EDT - 3 years ago

Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26

Anebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants

Jul 5, 2022, 8:00 AM EDT - 3 years ago

Anebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants

Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Jul 5, 2022, 6:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

Jun 23, 2022, 4:00 PM EDT - 3 years ago

Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer

May 24, 2022, 4:00 PM EDT - 3 years ago

Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

May 11, 2022, 9:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission

Apr 1, 2022, 7:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission

Anebulo Pharmaceuticals Reports Q2 Financial Results, Plans To Develop Therapy For Acute Cannabinoid Intoxication

Feb 11, 2022, 9:13 AM EST - 3 years ago

Anebulo Pharmaceuticals Reports Q2 Financial Results, Plans To Develop Therapy For Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates

Feb 11, 2022, 8:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates

Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations

Jan 6, 2022, 7:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations

Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

Jan 6, 2022, 7:00 AM EST - 3 years ago

Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director

Jan 4, 2022, 7:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director

Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication

Jan 3, 2022, 7:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Nov 12, 2021, 8:00 AM EST - 4 years ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose

Oct 13, 2021, 8:00 AM EDT - 4 years ago

Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose

Overdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem

Oct 12, 2021, 8:59 AM EDT - 4 years ago

Overdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem

CBD-Focused Anebulo Pharma Posts Q4 & Full Year 2021 Earnings, Launching Phase 2 Cannabis Overdose Clinical Trials

Sep 23, 2021, 10:49 AM EDT - 4 years ago

CBD-Focused Anebulo Pharma Posts Q4 & Full Year 2021 Earnings, Launching Phase 2 Cannabis Overdose Clinical Trials

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update

Sep 22, 2021, 4:05 PM EDT - 4 years ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update

Anebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial

Sep 13, 2021, 8:00 AM EDT - 4 years ago

Anebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial

Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 7, 2021, 8:00 AM EDT - 4 years ago

Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Anebulo Pharmaceuticals Announces Formation of Scientific Advisory Board, Names First Two Members

Aug 12, 2021, 8:00 AM EDT - 4 years ago

Anebulo Pharmaceuticals Announces Formation of Scientific Advisory Board, Names First Two Members

Cannabinoid-Focused Anebulo Pharma Posts Q3 Earnings, On Schedule To Start Cannabis Overdose Clinical Trials

Jun 22, 2021, 10:27 AM EDT - 4 years ago

Cannabinoid-Focused Anebulo Pharma Posts Q3 Earnings, On Schedule To Start Cannabis Overdose Clinical Trials

Anebulo Pharmaceuticals Reports Recent Business Highlights and Announces Third Quarter Fiscal Year 2021 Financial Results

Jun 21, 2021, 4:05 PM EDT - 4 years ago

Anebulo Pharmaceuticals Reports Recent Business Highlights and Announces Third Quarter Fiscal Year 2021 Financial Results

longandon
longandon Jul. 31 at 7:15 PM
$ANEB so this English aron guy is kinda like that Tang guy that buys up bio or take the private? Anyone know about his previous companies ?
0 · Reply
YouVSYou
YouVSYou Jul. 27 at 3:12 AM
$ANEB $LIDR classic Golden Cross Launch pads We’ve found a few that haven’t gotten sent yet 😀
0 · Reply
davis8uni
davis8uni Jul. 25 at 12:25 PM
$ANEB
0 · Reply
davis8uni
davis8uni Jul. 25 at 2:00 AM
$ANEB
0 · Reply
davis8uni
davis8uni Jul. 24 at 12:12 PM
$ANEB
0 · Reply
YGLD
YGLD Jul. 24 at 11:23 AM
No +100% Gappers 😴 No Crazy PR Runners 😴 No After Hours Stock From Last Night Making Any Moves 😴 Very Low Volume Day Ahead 📉 $DNUT $ANEB $YYAI $AMOD $SPY
0 · Reply
davis8uni
davis8uni Jul. 24 at 9:09 AM
$ANEB Appreciate the transparency! He is killing it. Must watch! https://www.youtube.com/watch?v=xUO2eE5IbvM
0 · Reply
M1LL5
M1LL5 Jul. 24 at 3:29 AM
$ANEB $DNUT 👀
0 · Reply
YGLD
YGLD Jul. 24 at 1:21 AM
A Stop Loss Is An Insurance Policy Against A Big Loss 📝 $DNUT $ANEB $YYAI $AMOD $SPY
2 · Reply
YGLD
YGLD Jul. 24 at 1:20 AM
It Cost $0.00 To Wait For A Good Trading Setup 📝 $DNUT $ANEB $YYAI $AMOD $SPY
0 · Reply
Scratcher
Scratcher Jul. 24 at 12:32 AM
$ANEB this is the ANEB board right ?!?!
0 · Reply
SniperPro
SniperPro Jul. 23 at 11:25 PM
🤑 Bulls Make Money, Bears Make Money, Pigs Get Slaughtered... 🤑 🔥🔥🔥 $GPRO 70% $IXHL 110% $ABVX 610% $LXRX 300% $ANEB 82% 🔥🔥🔥 Give us two weeks and we move up!!!!! That's the game!!!! The Eiffel Tower is shaking… not from wind, but from drama... 🤣🤣🤣🤣🤣 Ain’t got time for little men trying to play big... Tiny minnows fish to the left, WHALES TO THE RIGHT.... Know your place in the natural order.... BOOOM 🔥🔥🔥 BTW.... My finances are NONE OF YOUR FUCKING BUSINESS!!!💦 ...
1 · Reply
topstockalerts
topstockalerts Jul. 23 at 8:31 PM
Top Gainers $ABVX $WLGS $ANEB $YYAI $PAPL
0 · Reply
CarpeDiem69
CarpeDiem69 Jul. 23 at 7:29 PM
$ANEB $WLGS $AGH $ZOOZ check out $PROP
1 · Reply
PaulLaurent
PaulLaurent Jul. 23 at 7:27 PM
📊🔥 Top Gainers Update 💰🚨 $ANEB $CLSD $ZOOZ $PALI $SDST
0 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jul. 23 at 7:19 PM
$WLGS $ANEB $AMOD
1 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jul. 23 at 7:08 PM
$WLGS AH runner. $9.66 last run. heavily shorted. short squeeze is starting. micro float 29m. big volume 615M. $22M cash. $100M bitcoin. $71M contract. $15M +$15M two acquisition. new $ANEB and $AMOD ww
0 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jul. 23 at 6:59 PM
$WLGS $22M cash. $100M bitcoin. $71M contract. $15M +$15M two acqusition. new $ANEB and $AMOD ww
0 · Reply
YouVSYou
YouVSYou Jul. 23 at 6:57 PM
$IBG on this pullback from recent run to $1.48 last week. Looking for $1 News next week $ANEB $YYAI $AGH $UAVS
0 · Reply
CAPITALWHISPERER
CAPITALWHISPERER Jul. 23 at 6:48 PM
$WLGS $ANEB $AMOD
0 · Reply
GAPMoney
GAPMoney Jul. 23 at 6:43 PM
$OPEN what you all think about $ANEB ?
0 · Reply